Status:

UNKNOWN

Lacosamide in Neonatal Status Epilepticus

Lead Sponsor:

Sherief Abd-Elsalam

Conditions:

Epilepsy

Eligibility:

All Genders

Up to 28 years

Phase:

PHASE3

Brief Summary

Lacosamide in neonatal status epilepticus

Detailed Description

The study will assess the efficacy of Lacosamide in neonatal status epilepticus

Eligibility Criteria

Inclusion

  • neonates with status epilepticus

Exclusion

  • congenital anomalies or organ dysfunction

Key Trial Info

Start Date :

March 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2024

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT05291455

Start Date

March 1 2022

End Date

April 1 2024

Last Update

March 22 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kafrelsheikh University

Tanta, Kafrelsheikh, Egypt

Lacosamide in Neonatal Status Epilepticus | DecenTrialz